Altmetric

Defining the relationship between COPD and CVD: what are the implications for clinical practice?

File Description SizeFormat 
1753465817750524.pdfPublished version617.69 kBAdobe PDFView/Open
Title: Defining the relationship between COPD and CVD: what are the implications for clinical practice?
Authors: Morgan, AD
Zakeri, R
Quint, JK
Item Type: Journal Article
Abstract: Cardiovascular diseases (CVDs) are arguably the most important comorbidities in chronic obstructive pulmonary disease (COPD). CVDs are common in people with COPD, and their presence is associated with increased risk for hospitalization, longer length of stay and all-cause and CVD-related mortality. The economic burden associated with CVD in this population is considerable and the cumulative cost of treating comorbidities may even exceed that of treating COPD itself. Our understanding of the biological mechanisms that link COPD and various forms of CVD has improved significantly over the past decade. But despite broad acceptance of the prognostic significance of CVDs in COPD, there remains widespread under-recognition and undertreatment of comorbid CVD in this population. The reasons for this are unclear; however institutional barriers and a lack of evidence-based guidelines for the management of CVD in people with COPD may be contributory factors. In this review, we summarize current knowledge relating to the prevalence and incidence of CVD in people with COPD and the mechanisms that underlie their coexistence. We discuss the implications for clinical practice and highlight opportunities for improved prevention and treatment of CVD in people with COPD. While we advocate more active assessment for signs of cardiovascular conditions across all age groups and all stages of COPD severity, we suggest targeting those aged under 65 years. Evidence indicates that the increased risks for CVD are particularly pronounced in COPD patients in mid-to-late-middle-age and thus it is in this age group that the benefits of early intervention may prove to be the most effective.
Issue Date: 22-Jan-2018
Date of Acceptance: 4-Dec-2017
URI: http://hdl.handle.net/10044/1/56755
DOI: https://dx.doi.org/10.1177/1753465817750524
ISSN: 1753-4666
Publisher: SAGE Publications
Start Page: 1753465817750524
End Page: 1753465817750524
Journal / Book Title: Therapeutic Advances in Respiratory Disease
Volume: 12
Replaces: http://hdl.handle.net/10044/1/56530
10044/1/56530
10044/1/54596
http://hdl.handle.net/10044/1/54596
Copyright Statement: Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Sponsor/Funder: British Lung Foundation
Funder's Grant Number: RG14-5
Keywords: COPD
cardiovascular disease comorbidities
cardiovascular disease risk management
chronic obstructive pulmonary disease
Respiratory System
Publication Status: Published
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons